Thermo Fisher Scientific Inaugurates New Bioanalytical Lab in USA

Clinical Research Thermo Fisher Scientific Inaugurates New Bioanalytical Lab in USA

20.10.2022 Source: Press release Thermo Fisher Scientific

Thermo Fisher Scientific’s new bioanalytical lab is located in Richmond, Virginia and will help to accelerate the firm’s drug discovery process and expand its clinical research operations in the region.

Thermo Fisher Scientific has expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia, USA.
(Source: ©copyright John Still for Thermo Fisher Scientific)

North Carolina/USA – Thermo Fisher Scientific has expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia. The new unit will support increasing demand across biopharma for consistent, high-quality laboratory services to accelerate drug development. The 59,000-square-foot facility is part of the previously announced 97-million-dollar investment by the company to expand its bioanalytical laboratory operations in Richmond and add more than 500 jobs over the next three years.

The current laboratory services operation in Richmond, which Thermo Fisher acquired through the purchase of PPD in December 2021, now comprises more than 350,000 square feet, making it one of the largest laboratories of its kind in the world. The entire Richmond operation employs about 1,300 local professionals, including Ph.D.-level scientists, analytical laboratory staff and other scientific professionals. The bulk of the expansion with this new facility will occur in liquid chromatography-mass spectrometry for drug discovery through to clinical testing, as well as subsequent enhancements in cell and gene therapy, biomarkers, vaccine sciences and immunochemistry.

“The ongoing expansion of our bioanalytical operations builds on the growth of our drug development expertise over nearly four decades, enabling us to provide customers with high-quality lab services to advance their clinical research programs,” said David M. Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific. “These additions will enable us to meet the growing needs of our customers delivering life-changing therapies.”

(ID:48676051)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.